What Spazmalin Treats: Main Uses and Benefits

The combination of analgesic and antispasmodic agents is considered relevant in conditions involving smooth muscle spasm, and is applied across domains where additional symptomatic support is needed for symptoms related to physical discomfort. Spazmalin is utilized when symptoms intensify and supportive relief is required, providing support that helps ease the overall symptom burden and offers symptomatic relief that helps patients cope more steadily.

This medicine may assist with symptom clusters that appear suddenly or fluctuate, such as those that create noticeable physiological strain, including situations presenting with systemic or localized discomfort. It is generally applied during phases of increased distress or discomfort in conditions characterized by periods of heightened symptoms or recurrent episodes. It supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

Quick Fact: Focus on Symptom Clusters

This medicine is applicable within clinical settings that involve acute or unstable symptom patterns, helping with short-term symptom stabilization in contexts involving heightened systemic burden.

Who Can and Cannot Use Спазмалин?

The eligibility to use Спазмалин (Metamizole Sodium, Pitofenone, Fenpiverinium Bromide) is strictly defined by regulatory documents, with key restrictions related to the severe, though rare, risk of agranulocytosis from the Metamizole component.

Populations Explicitly Contraindicated

Спазмалин is absolutely contraindicated and must not be used by patients with:

• A history of agranulocytosis or impaired bone marrow function.
• Known hypersensitivity (allergy) to any component, pyrazolone derivatives, or other NSAIDs.
• Gastrointestinal obstruction or megacolon.
• Pregnancy (especially the third trimester) and breastfeeding.

Age and Conditional Restrictions

The standard population for use is adults and adolescents 15 years of age and older. Use in children under 15 years is restricted, often with contraindication for infants under 3 months. The medicine must be used with caution in patients with impaired renal function or impaired hepatic function and in those with anatomical narrowing of the gastrointestinal tract, such as pyloroduodenal stenosis.

The official regulatory profile for this combination product is defined primarily by the interaction characteristics of Metamizole Sodium (pharmacokinetic and pharmacodynamic) and Fenpiverinium Bromide (pharmacodynamic).

---

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	CYP Substrates (CYP3A4, CYP2B6, CYP2C19), Anticholinergic agents, and Antiplatelet agents.
Specific interacting medicines	Cyclosporine, Midazolam, Acetylsalicylic acid (Aspirin), Quetiapine, Methadone, Bupropion, Valproic acid, and Sertraline.
Mechanistic basis of interactions	Enzyme Induction: Metamizole is a moderate to strong inducer of CYP3A4, CYP2B6, and CYP2C19. Pharmacodynamic Interference: Metamizole inhibits the antiplatelet effect of acetylsalicylic acid.
Timing-based interaction rules	The interaction affecting antiplatelet efficacy may be prevented if acetylsalicylic acid is administered at least 30 minutes prior to Metamizole.
Interaction-related restrictions	Alcohol may intensify the sedative adverse effects of the anticholinergic component. Co-administration with other anticholinergic agents may lead to potentiated effects.

---

Interaction Classifications

Interactions are generally classified as Clinically Significant or Potentially Hazardous due to the risk of reduced therapeutic effect or potentiation of systemic effects. The pharmacokinetic constraints are most relevant when high dosages are used for periods longer than one day. The product’s interaction structure is defined by Metamizole’s metabolic activity, necessitating awareness of potential reduced exposure for certain co-administered drugs. This includes a critical pharmacodynamic constraint that requires a mandatory dose separation rule with antiplatelet agents.

Central Modulation of Pain and Temperature ️

This domain is mediated by Metamizole Sodium, which acts within the central nervous system (CNS). Its mechanism involves the inhibition of the COX-3 enzyme and the modulation of endogenous opioid and cannabinoid systems. These actions suppress the signaling of prostaglandin E2 in the spinal cord and hypothalamus, which influences nociceptive signal transmission and modulates the hypothalamic thermoregulatory set point.

---

Dual-Action Spasmolysis: Neurotropic and Myotropic

The combined action of Fenpiverinium Bromide and Pitofenone provides a dual-mode peripheral mechanism to reduce smooth muscle tone. Fenpiverinium exerts a neurotropic effect by blocking Muscarinic Receptors to interrupt nerve-driven contractions. Pitofenone provides a myotropic effect by directly blocking L-Type Calcium Channels in the muscle cell, limiting the Ca^2+ needed for contraction. This synergy addresses smooth muscle contraction via two distinct signaling pathways, influencing both the nervous command and the final cellular mechanism.

Спазмалин is administered via two primary routes: the oral route using tablets, and the parenteral route using a solution for injection, which is indicated for intramuscular (IM) or intravenous (IV) use.

---

Standard Dosing and Frequency

The standard dosing schedule defines the amount and frequency of intake.

Administration Type	Dosing Detail	Administration Condition
Oral (Adults)	Single dose of 1 to 2 tablets.	Tablets must be taken after eating and swallowed with water.
Maximum Daily Limit	The total daily dose must not exceed 6 tablets.	The oral course of treatment is restricted to a maximum duration of 3 days.
Parenteral	Dosing for injection is determined by medical personnel.	Intravenous administration requires the solution to be administered very slowly to meet procedural standards.

---

Special Population Guidelines

Guidelines for use include specific dose adjustments for children and adolescents. Pediatric dosing is reduced and based on age/weight, with defined maximum limits (e.g., ages 9 to 12 have a maximum daily dose of 2 tablets). Caution is required when administering this medicine to patients with impaired hepatic or renal function, as this may necessitate procedural modification.

The structure of use for Спазмалин is defined by a short-term duration requirement, which mandates that the oral course not exceed three days. The protocol also defines the acceptable routes of administration, the post-meal timing for the oral tablets, and requires a reduction in dose for specific pediatric groups and caution for patients with impaired organ function. This framework provides a standardized procedural protocol for its administration.

Research evidence / Overview of studies for Спазмалин

Evidence for Use in Acute Spasmodic Pain (Colic)

The fixed-dose combination of ingredients in this medicine was studied in research exploring outcomes related to physical discomfort associated with smooth muscle spasm, particularly in conditions characterized by fluctuating or episodic manifestations like renal, biliary, and digestive tract colic. This research involves studies that combine an analgesic component with antispasmodic agents, and includes components observed in studies examining smooth muscle activity. Research explored outcomes related to physical discomfort and how spasmodic symptoms evolved in observed patient populations.

However, the certainty around the specific benefit of the triple combination is considered moderate. There is a limited number of large-scale Randomized Controlled Trials (RCTs) specifically dedicated to examining the efficacy of this precise combination against alternative treatments for spasm. Furthermore, the follow-up durations in the existing studies were limited, reflecting only the short-term management of the acute episodes.

Evidence for Use in Acute Severe Pain and Fever

Research has extensively examined the primary component of this medicine, Metamizole Sodium, for its role in managing both acute severe pain (such as post-operative pain) and high body temperature (fever). The evidence base supporting this use includes Randomized Controlled Trials (RCTs) and Systematic Reviews and Meta-analyses. Studies explored outcomes related to systemic or functional imbalance, such as pain intensity reported or the patient's elevated body temperature.

Findings from these broader studies described measured patterns related to pain intensity and antipyretic effect. The evidence for the short-term analgesic and antipyretic component was found to be consistent across multiple studies, as described in scientific reviews.

Long-Term Research and Follow-up Duration

Clinical research for this medicine, which is generally applied in research contexts involving fluctuating or unstable symptoms, has concentrated almost entirely on research exploring short-term symptom changes. The follow-up durations in the key efficacy trials were limited, typically measuring outcomes over periods ranging from hours to a few days.

For this reason, long-term effects are not fully established. There is limited information for long-term outcomes regarding the durability of any measured response or the patterns of use beyond the acute episodes for which the medicine was studied for.

Key Studies & References

1. Assessment report - Referral under Article 31 of Directive 2001/83/EC metamizole-containing medicinal products INN

Common questions about Спазмалин (FAQ)

Q: What is the standard strength of the active ingredients in the tablet form?

The official product information specifies the exact quantities of the active components in each tablet. Each tablet contains Metamizole sodium 500 mg, Pitofenone hydrochloride 5 mg, and Fenpiverinium bromide 0.1 mg. This information reflects the standard combination of ingredients found in the product.

---

Q: Can other antispasmodic medicines be used in combination with Спазмалин?

Official regulatory documents indicate that combining this medicine with other analgesic, antipyretic (fever-reducing), or anti-inflammatory drugs may lead to an increased risk of allergic reactions. Since this medicine already contains both analgesic and antispasmodic components, official warnings highlight the potential for increased sensitivity when using related medications concurrently.

How to Store and Dispose of Спазмалин?

Storage of Спазмалин must strictly adhere to the conditions mandated by regulatory labeling to maintain product stability and safety.

Storage Requirements

This medication must be stored below 25 C (77 F) and must be protected from light and moisture. To ensure proper protection, the product should be kept in the original container and remain in the outer carton. It is specifically stated that the product must not be stored in the freezer. For safety, the medicine must always be kept out of the sight and reach of children.

Disposal Instructions

Discarding unused or expired Спазмалин must follow official environmental guidelines. The product must not be disposed of in household waste or wastewater. Patients are instructed to ask a pharmacist how to discard the medicine to ensure compliance with local requirements for pharmaceutical waste.